outlook. pleased our in strategic analysts and our demonstrates report is with My successful thanks previously which the consistent positive to today’s Kamada I'm Kamada’s transition Bob. call. your interest company of you, to investors third strong performance, communicated for participating in quarter and Thank and also for the
You the the recall this financial meaningfully that results in first compared will that year year. to six of focused last the would our half as second and we had improve months
performance FDA HEPAGAM, is beginning Our full consisting benefits our the to of approved of of that realize and significant acquired IgG indicates the WINRHOSDF. portfolio CYTOGAM, quarter in the VARIZIG business third
our can a our sales say year. dependency market. we plasma-derived rapid specialty profitability diversified, and In fact, On the our out Kedrion I last sales Takeda half that of and past aircraft to KEDRAB completed in leader drivers to of transition laid This I IgG into a included commercial our integrated and expected confidently GLASSIA now have key royalty fully the portfolio, our sales second call, on for global income. from company GLASSIA the and
in of of of of and the of gross growth quarter in XX% revenues contributors sales million, quarter from All to stability XXXX third the of the we XXXX. indeed representing total in margins in XX%, XX% and the a $XX.X generated these the were third important XX% second which quarter increase year-over-year up
And for increase margin. annual our Our consistent first $XX.X the and adjusted was last XX% is quarter year, the represents EBITDA guidance XX% representing This a a it EBITDA for compared with adjusted representing third months $X the million, nine margin. was EBITDA year. to XX% level a of million, as
consecutive operations. significant cash our of This XXXX. positive of September $XX.X We quarter, profitable activities position cash as in from generation generate is million flow third to continue also operating commercial a indicative resulting for cash the of XX,
a XXXX $XXX to between XXXX XX%. XX% expected million represents guidance to of more revenue further XX% than guidance $XXX sales enhanced it to EBITDA. X.Xx of profitability our to expect million and quarter fourth in report revenue, we growth will are reiterating a and the as EBITDA result This of with We a margins be XX% increase XXXX full-year
year XXXX. of and to foreseeable gain we in rate farther we traction again the quarter. a strong continue markets focus portfolio Looking for continues last and delivered at the in the The growth multiple profitability acquired Kamada full sales to late double-digit during beyond year ahead, FDA-approved immunoglobulins third
recent rapidly As a approximately grow revenues will product revenues presence the anticipate acquired reminder, part XXXX establishment am to key to in year. medical generated $XX U.S. physicians direct making the our year-over-year opportunities medical promoting months, of and in The pleased new professional we progress specialty with and I this professionals direct good operations sales U.S.-based we that who this gross established sales margins of we that of portfolio already collective immunoglobulin over XX% report beginning experienced is healthcare our in U.S. and other the of our at engagement affairs significantly million and meetings. market. through in deployed market, as plasma-derived in of portfolio a the team team
to working activity and Association This Heart the Lung XXXX their product first represents being addressing U.S. activity high Study over scientific presented American this Throughout the of in the physicians, and American team and the of the time to for and Transplant educate decade premium inquiries. a clinical Our conferences participated area Congress, major its Disease. medical supported by of including to Liver our Medical team Society International while is transplant, in Affairs U.S., field-based
contributing by of by operating sales for approximately highlight generated this to agreement be be data expected received symposiums in will would standpoint, this fourth have educational will in seeking portfolio the impact are U.S. this products U.S., strategic different the driver I signed our markets. a growth in anticipated we Latin period, key that when key agreement principally XXXX. our international to of continued are the this important these revenues understanding markets. international first positive the recently four of $XX.X strongly the agreement on in meaningful while one VARIZIG, million from from From products to who the encouraged demand. related of We conducting to a positive physicians the half supply the supply the new Outside believe international grow are the product This to to quarter publish we portfolio, the continue to America. to growth feedback clinical our balance in to ability the during will organization be validates newly half a extended, us agreement as of sales acquired generate
with the $XX This a the [award] products all addition, recently second from years tender an for of [ph] CBS, of four of total service existing an the secures supply agreement for additional for Canadian secured In option million. excluding Blood we with extension territories significant Canadian that with for value Services, April three X-year CBS provinces supply product for approximate market. The ongoing and additional to supplier an a of period, all the to for Canadian up Canadian the in X, product years. of Quebec. extension extend on two is manages commencing XXXX, CBS
strategic agreements leveraging production our through to of receipt contract approval in half key in of products first to encouraged underscore [ph] I and selling four the to distribution largest expect These our additional CYTOGAM, pursue proactive ahead are highly We our Israeli should add commitment] Kamada's the commercial at of continue that we also long acquired the strategic by the standing XXXX. for of efforts during continuing FDA opportunities relationship territories assets. facility significant these the new us. are supply of [field
the to rabies pandemic Kamada. XX% the as moderation KEDRAB gain the believe which our next pandemic Let's U.S. million share Based this again the outdoor it year, to driver continued and the continues in COVID to product immunoglobulin. growth sales travel of remain to and market on KEDRAB, on market. of by should an nine gross margins activities, encouraged months in comparison move the trend the in third pre-COVID also first years market more $XXX levels. for through will in the continue generates for significantly increasingly and we product during sales We the be U.S. I few grew quarter important highlight over by the increased that than us expect Kedrion
we royalty to GLASSIA Next, to on receive Takeda. continue income sales
quarter, we the During of income $X.X generated royalty million. third
Takeda pure GLASSIA for represents from I to Takeda our income profit [indiscernible] extends royalty reminder, Kamada. a out XXXX. As royalty
future Now, begin let's collection at plasma Plasma, farther U.S.-based ahead our little catalysts. company. look I'll Kamada a with
source plasma goal the remain additional expanding We hyperimmune to of into and continue at plasma on collection Kamada’s Texas collection market our represented in the plasma product entry centers further [normal collection [ph]. this of the enhance focused in becoming open strategic a to plasma] XXXXacquisition center and company. of early to plasma and capacity our specialty Our U.S. plans Houston, our fully supported U.S. center supply specialty the integrated advance
future. and In in the collection site a the to center be in near initiated finalizing we're the of process in second for Texas construction of selection activities startup with fact,
our position the revenue expected previously, of enhance capabilities chain. to boost various in said continued markets, have IgG our we As expansion and collection supply plasma competitive our strengthen is planned growth
Let's now in InnovAATe turn over treatment and pivotal the Inhaled efficacy for ongoing InnovAATe AAT AAT Phase safety clinical trial products of that our deficiency. is to X the evaluating
To of was enrolled across have following six XX has the this accelerate. two sites period now already recall for in-light date, year, were and treatment that recently the early trial who of the study the patients years to Netherlands. at the pandemic, will duration including patients expanded site You COVID initial XX treatment begun study enrollment Europe. include completed [Indiscernible] the
were reported. treatment prematurely related This drug the level adherence of and of events none through Importantly, discontinued high patients is adverse no treatment serious the encouraging. patient
recommended trial extended modification. of for XX%. indicators Additionally, including an also DSMB, criteria with between expected FEVX important Monitoring the while to first recently based patients independent without is study of supported the also Data DSMB time enrollment. XX% Moreover, The patients that date, limitations. expansion with Board, process on to as the subjects only since and include further criteria to severe and inclusion monitoring limited trial encouraging and patients to over include to XX%, the continue the Safety safety criteria airflow the part expedite the observed routine FEVX allows with period planned change us the This initiation, include
of opportunities progress] with intend discuss shorten to we meet the explore [study with first XXXX through the regulatory and and Importantly, potential [ph] to to pathway. FDA EMA half
for most advanced augmentation In EU. the $X our drive the in on growth for AAT billion the the our the longer-term industry deficiency, plasma years AAT summary, be a annual outlook foreseeable prospects, strategy well as near-term which excited global growth about believe is and we and Chaime profit substantial milestones creating I'll over to the next that, for U.S. is results. a third as uniquely and generation in Kamada ahead catalyst investigational specialty the financial us. Inhaled his in value therapy as in double-digit now of transformational exists market fronts products positioned With month have our multiple corporate review the turn XXXX AAT We're opportunity the as in to As please. ahead. commercial market, execute to with already Chaime, sales of our leader expected growing call on we continue all the to quarter quarters the in for over
